Paper23219031
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI).
Bialer M and 5 others. Epilepsy Res, 2013. Cited by 196 papers, by iCite.
Cite this record
ConductScience Library. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Papers, record 23219031. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23219031
- Disease
- Focal-onset seizure27 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI).
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anticonvulsants | Major topic |
| Congresses as Topic | Major topic |
| Drugs, Investigational | Major topic |
| Epilepsy | Major topic |
| Research Report | Major topic |
| Animals | |
| Clinical Trials as Topic | |
| Humans | |
| Israel |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01397968 | Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures | Derived from the trial | Yes |
Source ClinicalTrials.gov
Cited by113
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 196 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42977736 | Epilepsy: epidemiology, risk factors, classification, pathophysiology, clinical features, diagnosis and management. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42977736 | PubMed |
| 42246053 | The cumulative impact of seizures: the science underlying how seizures beget seizures. | Front Neurol | 2026 | https://conductscience.org/library/papers/42246053 | PubMed |
| 42111266 | Pyroptosis in epilepsy: from pathophysiological mechanisms to therapeutic strategies. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42111266 | PubMed |
| 41951906 | The Discovery of Cenobamate: A Drug with High Efficacy in Drug-Resistant Epilepsy. | CNS Drugs | 2026 | https://conductscience.org/library/papers/41951906 | PubMed |
| 41915362 | The Complexity and Challenges of Developing Effective Epilepsy Therapies: Lessons to be Learned from Comparing Cenobamate, Carisbamate, and Padsevonil. | CNS Drugs | 2026 | https://conductscience.org/library/papers/41915362 | PubMed |
| 41764707 | Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades. | Drugs | 2026 | https://conductscience.org/library/papers/41764707 | PubMed |
| 41322155 | Dual-functional pH-sensitive nanoliposomes modified with CD47 mimicry peptide enhance icariin delivery to attenuate neuroinflammation and oxidative stress in epilepsy. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/41322155 | PubMed |
| 41155637 | IL-1β and HMGB1 in Epileptogenesis: Recent Advances and Clinical Translation. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41155637 | PubMed |
| 41059206 | Clinical predictors and concomitant antiseizure medications effects on seizure control in relation to plasma cenobamate concentration: a multicenter retrospective study. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41059206 | PubMed |
| 40526193 | Pyroptosis in Alzheimer's Disease: Mechanisms and Therapeutic Potential. | Cell Mol Neurobiol | 2025 | https://conductscience.org/library/papers/40526193 | PubMed |
| 40384045 | Cenobamate in Real-Word Scenario: Results on Efficacy, Side Effects, and Retention Rate in a Single Center Retrospective Study. | Brain Behav | 2025 | https://conductscience.org/library/papers/40384045 | PubMed |
| 39853501 | Targeting Kv7 Potassium Channels for Epilepsy. | CNS Drugs | 2025 | https://conductscience.org/library/papers/39853501 | PubMed |
| 39684724 | Cenobamate, a New Promising Antiseizure Medication: Experimental and Clinical Aspects. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39684724 | PubMed |
| 39251813 | Inflammasome components as new therapeutic targets in inflammatory disease. | Nat Rev Immunol | 2025 | https://conductscience.org/library/papers/39251813 | PubMed |
| 38791515 | Initial Despair and Current Hope of Identifying a Clinically Useful Treatment of Myocardial Reperfusion Injury: Insights Derived from Studies of Platelet P2Y12 Antagonists and Interference with Inflammation and NLRP3 Assembly. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38791515 | PubMed |
| 38740765 | Renal macrophages and NLRP3 inflammasomes in kidney diseases and therapeutics. | Cell Death Discov | 2024 | https://conductscience.org/library/papers/38740765 | PubMed |
| 38675544 | New Findings on the Crystal Polymorphism of Imepitoin. | Molecules | 2024 | https://conductscience.org/library/papers/38675544 | PubMed |
| 38489314 | Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study. | PLoS One | 2024 | https://conductscience.org/library/papers/38489314 | PubMed |
| 38449838 | Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials. | EClinicalMedicine | 2024 | https://conductscience.org/library/papers/38449838 | PubMed |
| 37893198 | The NLRP3 Inflammasome in Neurodegenerative Disorders: Insights from Epileptic Models. | Biomedicines | 2023 | https://conductscience.org/library/papers/37893198 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| CENOBAMATE | CHEMBL3989949 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3989949 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23219031
GET https://conductscience.org/api/papers/v1/23219031/cited_by?page=2